NASDAQ:ASND

Ascendis Pharma A/S (ASND) Stock Forecast, Price & News

$94.21

-1.29 (-1.35%)

(As of 09/26/2023 ET)

Compare

Today's Range: $92.69
▼
$96.54
50-Day Range: $86.50
▼
$103.97
52-Week Range: $64.33
▼
$134.52

Volume: 331,333 shs
Average Volume: 456,845 shs
Market Capitalization: $5.38 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $145.20

Ascendis Pharma A/S MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.70 Rating Score
Upside/Downside: 54.1% Upside
$145.20 Price Target
Short Interest: Bearish
7.94% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.37
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($9.91) to ($8.31) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

527th out of 964 stocks

Pharmaceutical Preparations Industry

228th out of 440 stocks

3.4

Analyst's Opinion

Consensus Rating
Ascendis Pharma A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $145.20, Ascendis Pharma A/S has a forecasted upside of 54.1% from its current price of $94.21.
Amount of Analyst Coverage
Ascendis Pharma A/S has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.94% of the outstanding shares of Ascendis Pharma A/S have been sold short.
Short Interest Ratio / Days to Cover
Ascendis Pharma A/S has a short interest ratio ("days to cover") of 18, which indicates bearish sentiment.
Change versus previous month
Short interest in Ascendis Pharma A/S has recently decreased by 5.02%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Ascendis Pharma A/S does not currently pay a dividend.
Dividend Growth
Ascendis Pharma A/S does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ASND.

3.5

News and Social Media Coverage

News Sentiment
Ascendis Pharma A/S has a news sentiment score of 1.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Ascendis Pharma A/S this week, compared to 4 articles on an average week.
Search Interest
5 people have searched for ASND on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.
Percentage Held by Insiders
40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($9.91) to ($8.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ascendis Pharma A/S is -8.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ascendis Pharma A/S is -8.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ascendis Pharma A/S has a P/B Ratio of 19.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ascendis Pharma A/S (NASDAQ:ASND) Stock

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

ASND Price History

30 days | 90 days | 365 days | Advanced Chart

ASND Stock News Headlines

September 23, 2023 | finance.yahoo.com

Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency

September 22, 2023 | finance.yahoo.com

Here’s What Caused the Volatility in Ascendis Pharma A/S (ASND)

September 27, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

September 22, 2023 | americanbankingnews.com

Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 20, 2023 | americanbankingnews.com

Short Interest in Ascendis Pharma A/S (NASDAQ:ASND) Declines By 5.0%

September 17, 2023 | americanbankingnews.com

Cantor Fitzgerald Reiterates "Overweight" Rating for Ascendis Pharma A/S (NASDAQ:ASND)

September 17, 2023 | americanbankingnews.com

Ascendis Pharma A/S (NASDAQ:ASND) Shares Gap Up to $100.23

September 15, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ascendis Pharma (ASND) and Laboratory (LH)

September 27, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

September 15, 2023 | finance.yahoo.com

Ascendis Pharma A/S (ASND) Soars 3.2%: Is Further Upside Left in the Stock?

September 15, 2023 | finance.yahoo.com

Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

September 14, 2023 | finance.yahoo.com

Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism

September 12, 2023 | msn.com

Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge

September 10, 2023 | finance.yahoo.com

Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week

September 7, 2023 | markets.businessinsider.com

Berenberg Bank Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

September 7, 2023 | markets.businessinsider.com

Bank of America Securities Sticks to Its Buy Rating for Ascendis Pharma (ASND)

September 6, 2023 | finance.yahoo.com

Ascendis Pharma A/S (NASDAQ:ASND) Q2 2023 Earnings Call Transcript

September 6, 2023 | finance.yahoo.com

Is Ascendis Pharma A/S (ASND) Too Good to Be True? A Comprehensive Analysis of a Potential ...

September 6, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Abbott Labs (ABT) and Thermo Fisher (TMO)

September 5, 2023 | finance.yahoo.com

New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism

September 5, 2023 | finance.yahoo.com

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

September 5, 2023 | finance.yahoo.com

Ascendis Pharma Reports Second Quarter 2023 Financial Results

September 5, 2023 | finance.yahoo.com

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

September 4, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Ascendis Pharma (spons ADRs)'s earnings report

August 28, 2023 | finance.yahoo.com

Wall Street Analysts Predict a 41.43% Upside in Ascendis Pharma A/S (ASND): Here's What You Should Know

August 28, 2023 | finance.yahoo.com

Wall Street Analysts Predict a 41.43% Upside in Ascendis Pharma A/S (ASND): Here's What You Should Know

August 24, 2023 | finance.yahoo.com

Here’s Why Ascendis Pharma A/S (ASND) Declined in Q2

See More Headlines

Receive ASND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ASND Company Calendar

Last Earnings: 11/09/2021
Today: 9/27/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ASND
CUSIP: N/A
CIK: 1612042
Web: www.ascendispharma.com
Phone: (457) 022-2244
Fax: 45-3694-4010
Employees: 797
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $145.20
High Stock Price Forecast: $192.00
Low Stock Price Forecast: $113.00
Forecasted Upside/Downside: +54.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.70
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($11.30)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-614,450,000.00
Net Margins: -500.93%
Pretax Margin: -500.07%
Return on Equity: -257.83%
Return on Assets: -58.01%

Debt

Debt-to-Equity Ratio: 7.39
Current Ratio: 3.52
Quick Ratio: 2.65

Sales & Book Value

Annual Sales: $53.93 million
Price / Sales: 99.83
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.87 per share
Price / Book: 19.34

Miscellaneous

Outstanding Shares: 57,150,000
Free Float: 34,291,000
Market Cap: $5.38 billion
Optionable: Optionable
Beta: 0.50

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Jan Moller Mikkelsen (Age 63)
Pres, CEO, Member of Exec. Board & Exec. Director

Mr. Scott T. Smith (Age 49)
CFO, Exec. VP & Member of Exec. Board

Ms. Lotte Sonderbjerg (Age 62)
Exec. VP, Chief Admin. Officer & Member of the Exec. Board

Mr. Michael Wolff Jensen L.L.M. (Age 52)
Exec. VP, Chief Legal Officer & Member of the Exec. Board

Mr. Peter Rasmussen (Age 54)
VP of Fin. & Principal Accounting Officer

Mr. Timothy J. Lee
Sr. Director of Investor Relations

Mr. Flemming Steen Jensen (Age 62)
Exec. VP of Product Supply & Quality - Endocrinology Rare Diseases

Dr. Kennett Sprogoe Ph.D. (Age 44)
Exec. VP of Research & Product Devel.

Dr. Birgitte Volck M.D. (Age 61)
Ph.D., Exec. VP and Head of Clinical Devel. & Medical Affairs - Endocrinology Rare Diseases

Dr. Jens Sigurd Okkels Ph.D. (Age 62)
Exec. VP of Product Devel.

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ASND Stock - Frequently Asked Questions

Should I buy or sell Ascendis Pharma A/S stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ASND shares.
View ASND analyst ratings or view top-rated stocks.
What is Ascendis Pharma A/S's stock price forecast for 2023?: 10 Wall Street research analysts have issued 12-month price targets for Ascendis Pharma A/S's stock. Their ASND share price forecasts range from $113.00 to $192.00. On average, they anticipate the company's stock price to reach $145.20 in the next twelve months. This suggests a possible upside of 54.1% from the stock's current price.
View analysts price targets for ASND or view top-rated stocks among Wall Street analysts.
How have ASND shares performed in 2023?: Ascendis Pharma A/S's stock was trading at $122.13 on January 1st, 2023. Since then, ASND shares have decreased by 22.9% and is now trading at $94.21.
View the best growth stocks for 2023 here.
When is Ascendis Pharma A/S's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our ASND earnings forecast.
How were Ascendis Pharma A/S's earnings last quarter?: Ascendis Pharma A/S (NASDAQ:ASND) posted its earnings results on Tuesday, November, 9th. The biotechnology company reported ($1.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.60) by $1.13. The biotechnology company had revenue of $1.31 million for the quarter, compared to analysts' expectations of $1.60 million. Ascendis Pharma A/S had a negative trailing twelve-month return on equity of 257.83% and a negative net margin of 500.93%. During the same quarter in the prior year, the firm earned ($2.70) EPS.
What ETFs hold Ascendis Pharma A/S's stock?: ETFs with the largest weight of Ascendis Pharma A/S (NASDAQ:ASND) stock in their portfolio include Harbor Health Care ETF (MEDI), Putnam BioRevolution ETF (SYNB), Virtus LifeSci Biotech Products ETF (BBP), BNY Mellon Innovators ETF (BKIV), Global X Guru Index ETF (GURU), Harbor Disruptive Innovation ETF (INNO), Fidelity Disruptive Medicine ETF (FMED) and American CenturyFocused Dynamic Growth ETF (FDG).
What other stocks do shareholders of Ascendis Pharma A/S own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

When did Ascendis Pharma A/S IPO?: (ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.
What is Ascendis Pharma A/S's stock symbol?: Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."
Who are Ascendis Pharma A/S's major shareholders?: Ascendis Pharma A/S's stock is owned by a number of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (19.58%), Artisan Partners Limited Partnership (10.85%), Davidson Kempner Capital Management LP (0.00%), Capital International Investors (3.48%), TimesSquare Capital Management LLC (1.34%) and Spyglass Capital Management LLC (1.15%).
How do I buy shares of Ascendis Pharma A/S?: Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ascendis Pharma A/S's stock price today?: One share of ASND stock can currently be purchased for approximately $94.21.
How much money does Ascendis Pharma A/S make?: Ascendis Pharma A/S (NASDAQ:ASND) has a market capitalization of $5.38 billion and generates $53.93 million in revenue each year. The biotechnology company earns $-614,450,000.00 in net income (profit) each year or ($11.30) on an earnings per share basis.
How many employees does Ascendis Pharma A/S have?: The company employs 797 workers across the globe.
How can I contact Ascendis Pharma A/S?: Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The official website for the company is www.ascendispharma.com. The biotechnology company can be reached via phone at (457) 022-2244, via email at ir@ascendispharma.com, or via fax at 45-3694-4010.

This page (NASDAQ:ASND) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ascendis Pharma A/S (ASND) Stock Forecast, Price & News

Ascendis Pharma A/S MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Ascendis Pharma A/S (NASDAQ:ASND) Stock

ASND Price History

ASND Stock News Headlines

ASND Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ASND Stock - Frequently Asked Questions

Overall MarketRank^™